{
    "eid": "2-s2.0-85076565560",
    "title": "A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma",
    "cover-date": "2019-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "capmatinib",
        "HCC",
        "INC280",
        "MET inhibitor",
        "phase II"
    ],
    "authors": [
        "Shukui Qin",
        "Stephen Lam Chan",
        "Wattana Sukeepaisarnjaroen",
        "Guohong Han",
        "Su Pin Choo",
        "Virote Sriuranpong",
        "Hongming Pan",
        "Thomas Yau",
        "Yabing Guo",
        "Minshan Chen",
        "Zhenggang Ren",
        "Jianming Xu",
        "Chia Jui Yen",
        "Zhong Zhe Lin",
        "Luigi Manenti",
        "Yi Gu",
        "Yongjian Sun",
        "Ralph Tiedt",
        "Lu Hao",
        "Wenjie Song",
        "Tawesak Tanwandee"
    ],
    "citedby-count": 35,
    "ref-count": 30,
    "ref-list": [
        "AASLD guidelines for the treatment of hepatocellular carcinoma",
        "Global cancer statistics",
        "Cancer statistics, 2013",
        "MET inhibitors for treatment of advanced hepatocellular carcinoma: a review",
        "Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma",
        "Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype",
        "Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma",
        "Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma",
        "A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma",
        "Developing c-MET pathway inhibitors for cancer therapy: progress and challenges",
        "c-MET as a potential therapeutic target and biomarker in cancer",
        "c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma",
        "Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for MET-targeting therapy",
        "A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3",
        "Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC)",
        "Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors",
        "Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: a single-arm phase Ib/II study",
        "Sorafenib in advanced hepatocellular carcinoma",
        "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial",
        "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial",
        "Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial",
        "Final data from a phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC)",
        "Phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC): final data including long-term outcomes",
        "Second-line tivantinib (ARQ 197) versus placebo in patients with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial",
        "Tivantinib for the treatment of hepatocellular carcinoma",
        "Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro",
        "Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1",
        "Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion"
    ],
    "affiliation": [
        {
            "affiliation-city": "Shanghai",
            "@id": "117744602",
            "affilname": "China Novartis Institutes for BioMedical Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117744602",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hangzhou",
            "@id": "60118427",
            "affilname": "Sir Run Run Shaw Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60118427",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60088470",
            "affilname": "307 Hospital of PLA",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60088470",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60082502",
            "affilname": "Sun Yat-Sen University Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Tainan",
            "@id": "60073386",
            "affilname": "National Cheng Kung University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073386",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Xi'an",
            "@id": "60069708",
            "affilname": "Xijing Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069708",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": null,
            "@id": "60024787",
            "affilname": "Prince of Wales Hospital Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024787",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60009860",
            "affilname": "Fudan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009860",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Cambridge",
            "@id": "60006840",
            "affilname": "Novartis Institutes for BioMedical Research, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006840",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60002593",
            "affilname": "Southern Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002593",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "100642684",
            "affilname": "Nanjing Bayi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100642684",
            "affiliation-country": "China"
        }
    ],
    "funding": [
        "Bayer",
        "Novartis",
        "MET",
        "Celgene",
        "Shire",
        "Novartis Pharmaceuticals Corporation",
        "BMS",
        "Eisai"
    ]
}